151 related articles for article (PubMed ID: 31338169)
1. Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience.
Hartinger JM; Satrapová V; Hrušková Z; Tesař V
Eur J Hosp Pharm; 2019 Jul; 26(4):210-213. PubMed ID: 31338169
[TBL] [Abstract][Full Text] [Related]
2. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
3. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis.
Garzanova LA; Ananyeva LP; Koneva OA; Desinova OV; Starovoytova MN; Ovsyannikova OB; Shayakhmetova RU; Glukhova SI
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861145
[TBL] [Abstract][Full Text] [Related]
6. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
8. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis.
Odler B; Windpessl M; Krall M; Steiner M; Riedl R; Hebesberger C; Ursli M; Zitt E; Lhotta K; Antlanger M; Cejka D; Gauckler P; Wiesholzer M; Saemann M; Rosenkranz AR; Eller K; Kronbichler A
Front Immunol; 2021; 12():760708. PubMed ID: 34777374
[TBL] [Abstract][Full Text] [Related]
9. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
12. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
Raghavan P; Sreenath S; Cherian S; Shenoy PD
Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature.
Crayne CB; Eloseily E; Mannion ML; Azerf SP; Weiser P; Beukelman T; Stoll ML; Feig DI; Prescott Atkinson T; Cron RQ
Pediatr Rheumatol Online J; 2018 Nov; 16(1):71. PubMed ID: 30428889
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for non-infectious Uveitis and Scleritis.
Ng CC; Sy A; Cunningham ET
J Ophthalmic Inflamm Infect; 2021 Aug; 11(1):23. PubMed ID: 34396463
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
18. Rapid-Infusion Rituximab in a Pediatric Population.
Gaffney KJ; Dahl EM; Stanton MP; Starek E; Zembillas AS
J Pediatr Pharmacol Ther; 2020; 25(3):215-219. PubMed ID: 32265604
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis.
Bonnet I; Rousseau A; Duraffour P; Pouchot J; Nguyen CD; Gabison E; Seror R; Marotte H; Mariette X; Nocturne G
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33510042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]